

Baxter International Inc.
Key Product Line Sales
Period Ending June 30, 2003
(Unaudited)

(\$ in Millions)	Q2 2003	Q2 2002	% Growth	YTD 2003	YTD 2002	% Growth
BioScience						
Recombinants	253	247	3%	497	479	4%
Plasma Proteins ¹	230	241	(4%)	459	479	(4%)
Antibody Therapy	71	73	(4%)	138	149	(8%)
Transfusion Therapies ²	136	131	3%	270	261	3%
Medication Delivery						
IV Therapies ³	271	240	13%	519	463	12%
Drug Delivery	168	134	26%	329	266	24%
Electronic Infusion Systems	176	163	8%	327	314	4%
Anesthesia ⁴	220	162	36%	419	283	48%
Renal						
PD Therapy	337	304	11%	638	604	6%
HD Therapy	111	99	12%	214	196	9%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery and other plasma-based products.

² Formerly referred to as Fenwal.

³ Principally includes intravenous solutions and nutritional products.

⁴ Includes ESI Lederle.